<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with cancer often seek out nonconventional treatments for the relief of symptoms, as well as for disease-related outcomes, which include increasing survival, preventing disease recurrence, and “strengthening” their immune system [
 <xref rid="B1-pharmaceuticals-13-00455" ref-type="bibr">1</xref>,
 <xref rid="B2-pharmaceuticals-13-00455" ref-type="bibr">2</xref>,
 <xref rid="B3-pharmaceuticals-13-00455" ref-type="bibr">3</xref>]. The use of herbal medicine is one of the most popular of these modalities, with patients often believing that, because they are “natural”, these products are both effective and safe [
 <xref rid="B4-pharmaceuticals-13-00455" ref-type="bibr">4</xref>]. This belief is supported by the fact that many of the agents used in chemotherapy regimens are or were originally derived from botanical sources, such as paclitaxel (from the Pacific Yew tree, 
 <italic>Taxus brevifola</italic>), etoposide/VP-16 (from the wild mandrake, 
 <italic>Podophyllum peltatum</italic>), vinca alkaloids (from the rosy periwinkle, 
 <italic>Catharanthus roseus</italic>), and others [
 <xref rid="B5-pharmaceuticals-13-00455" ref-type="bibr">5</xref>]. However, the herbal medicinal products which are being acquired and self-administered by oncology patients often lack scientific evidence for efficacy, and they may be accompanied by direct toxic effects or negative herb–drug interactions.
</p>
